We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?
Read MoreHide Full Article
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
Eagle Pharmaceuticals (EGRX - Free Report) is a stock many investors are watching right now. EGRX is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock is trading with P/E ratio of 8.54 right now. For comparison, its industry sports an average P/E of 20.66. EGRX's Forward P/E has been as high as 18.93 and as low as 4.97, with a median of 6.53, all within the past year.
Investors should also recognize that EGRX has a P/B ratio of 1.83. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 4.30. Within the past 52 weeks, EGRX's P/B has been as high as 3.92 and as low as 1.39, with a median of 2.77.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. EGRX has a P/S ratio of 1.53. This compares to its industry's average P/S of 1.96.
QuidelOrtho (QDEL - Free Report) may be another strong Medical - Products stock to add to your shortlist. QDEL is a # 2 (Buy) stock with a Value grade of A.
QuidelOrtho sports a P/B ratio of 1.25 as well; this compares to its industry's price-to-book ratio of 4.30. In the past 52 weeks, QDEL's P/B has been as high as 4.45, as low as 0.92, with a median of 1.78.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Eagle Pharmaceuticals and QuidelOrtho are likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, EGRX and QDEL feels like a great value stock at the moment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
Eagle Pharmaceuticals (EGRX - Free Report) is a stock many investors are watching right now. EGRX is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock is trading with P/E ratio of 8.54 right now. For comparison, its industry sports an average P/E of 20.66. EGRX's Forward P/E has been as high as 18.93 and as low as 4.97, with a median of 6.53, all within the past year.
Investors should also recognize that EGRX has a P/B ratio of 1.83. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 4.30. Within the past 52 weeks, EGRX's P/B has been as high as 3.92 and as low as 1.39, with a median of 2.77.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. EGRX has a P/S ratio of 1.53. This compares to its industry's average P/S of 1.96.
QuidelOrtho (QDEL - Free Report) may be another strong Medical - Products stock to add to your shortlist. QDEL is a # 2 (Buy) stock with a Value grade of A.
QuidelOrtho sports a P/B ratio of 1.25 as well; this compares to its industry's price-to-book ratio of 4.30. In the past 52 weeks, QDEL's P/B has been as high as 4.45, as low as 0.92, with a median of 1.78.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Eagle Pharmaceuticals and QuidelOrtho are likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, EGRX and QDEL feels like a great value stock at the moment.